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ABSTRACT
Background: Hajj pilgrims are encouraged to take influenza and pneumococcal vaccines prior to their travel 
to safeguard against acute respiratory tract infections (ARTIs). It is unclear whether dual immunisation 
with influenza and pneumococcal vaccines have had any impact on ARTI symptoms. To this end, we have 
examined the data of the last several years to assess whether combined influenza and pneumococcal 
vaccination has affected the rate of ARTI symptoms among Hajj pilgrims. 
Materials and methods: Hajj pilgrims from United Kingdom, Australia, Saudi Arabia and Qatar who attended 
the congregation between 2005 and 2015 were included in this study. Data from surveillance studies 
or clinical trials involving Hajj pilgrims were used. In this analysis we have made use of the raw data to 
construct a trend line graph with the prevalence of combined cough and fever (as a proxy for ARTI) against 
the uptake of combined influenza and pneumococcal vaccines, and to estimate the relative risk (RR) of 
ARTI with 95% confidence interval (95% CI). 
Results: Data of a pooled sample of 9350 pilgrims, aged 0.5–90 years with a male to female ratio of 1.1, were 
analysed. Although vaccination uptake did not rise significantly over the years, there was also no observed me-
aningful benefit of combined vaccination (RR = 1.1; 95% CI 0.8–1.4), the rates of ARTI symptoms demonstrated 
a decline over the last several years. The findings of this analysis highlight that the prevalence of ‘cough and fever’ 
among Hajj pilgrims is on decline but the uptake of combined influenza and pneumococcal vaccines remains 
unchanged over years, and the decline can not be attributed to dual influenza and pneumococcal vaccination.
Conclusions: Acute respiratory tract infections among Hajj pilgrims are decreasing, it is unclear if the 
reduction is due to vaccine uptake, but the data and analysis have some limitations. 
(Int Marit Health 2018; 69, 4: 278–284)
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INTRODUCTION
Hajj is the largest annual religious mass gathering (MG) 
in which 2 to 3 million people assemble from different parts 
of the world in Makkah, the holiest city of Islam in the King-
dom of Saudi Arabia [1]. This event is spiritually significant 
for Muslims, being one of the five basic tenets of Islam 
and is found to increase belief in the quality and harmony 
among ethnic groups [2]. For over fourteen centuries, fol-
lowing the tradition of patriarch Abraham, Muslims from 
all corners of the world have been congregating in Makkah 
on specific dates of the ‘Hajj month’, the last month of the 
Arabic calendar [3]. Adult Muslims who are capable, both 
financially and physically, consider it a mandatory part of 
their religious duty to perform Hajj at least once in lifetime.
In this annual MG of more than two million people, the 
risk of communicable diseases is high [4]. Several large 
intercontinental outbreaks of infectious diseases have been 
linked to Hajj attendance [3–5]. Vaccinations against certain 
infections are routinely recommended for Hajj pilgrims, tour 
group officials, volunteers, healthcare workers, para-troops 
and seasonal workers [6]. Vaccination against four menin-
gococcal serogroups (A, C, W, and Y) is mandatory for all 
Hajj pilgrims and the local residents of pilgrimage sites [7]. 
Following the vaccination policy, the incidence of the labora-
tory-confirmed meningococcal disease has declined signifi-
cantly not only among pilgrims but also among residents [8]. 
Acute respiratory tract infections (ARTIs) can be caused by 
bacteria (e.g., Streptococcus pneumoniae), viruses (e.g., 
influenza) and other microbes. Children, elderly and indi-
viduals with lung and heart diseases, or other pre-existing 
medical conditions are at a higher risk of suffering from 
ARTIs. The risk of ARTIs, viral or bacterial, amplifies several 
times at Hajj [9]. In fact ARTIs are the leading causes of 
hospital attendance and admission among Hajj pilgrims 
[10]. Influenza and pneumococcal vaccines are viewed 
as the key preventive measures against these potentially 
serious diseases [11, 12]. The role of seasonal influenza 
vaccination in Hajj pilgrims is established [13, 14], but the 
role of combined influenza and pneumococcal vaccination 
in reducing ARTIs has not been assessed in a sufficiently 
large sample. To this end, we have examined the data of 
the last several Hajj years to assess whether dual influenza 
and pneumococcal vaccination has had any effect on the 
rate of ARTI among Hajj pilgrims. 
Thus, the objectives of this study are to examine the 
frequency of ARTI symptoms and the uptake of influenza 
and pneumococcal vaccines among Hajj pilgrims, and to 
evaluate the effect of dual influenza and pneumococcal 
vaccination on ARTIs among Hajj pilgrims.
MATERIALS AND METHODS
DATA SyNTHESIS 
The dataset used here comes from a database held 
by the senior authors of this publication at the National 
Centre for Immunisation Research and Surveillance of 
Vaccine Preventable Diseases, The Children’s Hospital at 
Westmead, New South Wales, Australia). The database 
contains data from various surveys, surveillance studies 
and clinical trials involving Hajj pilgrims from Qatar, Saudi 
Arabia, Australia and United Kingdom conducted between 
2005 and 2017. In the database, data for some years 
were incomplete or absent for this analysis. For instance, 
no, or only partial data (for this analysis) were available 
for the years 2006, 2008–2010, 2016 and 2017. For 
the pandemic year (2009), the data were retrieved from 
a published study [15], which provided data on participant 
demographics, uptake rate of influenza and pneumococcal 
vaccines, and prevalence of cough and fever symptoms. 
The study types, participant nationalities and Hajj years 
of the studies from where data have been used for this 
analysis are summarised in Figure 1. 
Individual subject data for the included years 2005, 
2007 and 2011–2015 were imported and combined in 
Figure 1. Studies from where individual subject data were collected for this analysis; RCT — randomised controlled trial
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a MS Excel sheet for analysis. ARTI was defined as a com-
bination of ‘cough and fever’; such a definition was chosen 
because it contains a symptom of the lower respiratory tract 
(i.e., cough) and a constitutional symptom (i.e., fever) and 
covers two of the key symptoms produced by both influen-
za and pneumococcus. The rates of combined cough and 
fever (as proxy for ARTI) were plotted against the uptake 
rates of combined influenza and pneumococcal vaccines 
to construct a  trend line graph. The relative risk (RR) of 
acquisition of ARTI among vaccinated versus unvaccinated 
pilgrims was estimated for each year with 95% confidence 
interval (95% CI) and finally for the pooled data. ‘At risk’ 
pilgrims were defined as those who were aged ≥ 65 years 
and/or had pre-existing medical conditions including heart, 
lung, kidney, liver, and neurological conditions and persons 
who were immunocompromised, including those with HIV 
infection, malignancy, functional or anatomical asplenia 
(which includes sickle cell disease, other haemoglobinopa-
thies, congenital or acquired asplenia, splenic dysfunction), 
or chronic steroid users. 
ETHICS AppROvAL
Ethical approval for the years 2013–2015 was obtained 
in Saudi Arabia from the Institutional Review Board (IRB) 
of King Abdullah Medical City, Makkah, (IRB Reference No: 
15-205), in Australia from the Hunter New England Hu-
man Research Ethics Committee (HNEHREC Reference No: 
13/07/17/3.04), and in Qatar from the Joint Institutional 
Review Board of Hamad Medical Corporation/Weill Cornell 
Medical College (JIRB Reference No: 13-00039). Ethics ap-
provals for the other years were obtained from appropriate 
authorities in the UK (Reference No: MREC 02/2/12), Saudi 
Arabia (Reference No: KACST: H-01-R-012) and Australia 
(HREC Reference No: 11/SCHN/162).
RESULTS 
The pooled sample size was 9350; in individual years 
or studies, the sample size varied considerably from 164 
to 4428 (Table 1). The pilgrims’ age ranged between 0.5 
years and 95 years with comparable age range across the 
studies. Median ages across individual studies fell within 
the age band of 34–49 years. In the pooled sample male 
to female ratio was 1.1, but the ratio varied considerably 
across the years: males outnumbered females in the years 
2005, 2007, 2012, and 2013, whereas in the remaining 
years females outnumbered males (Table 1). Overall, 19.2% 
of pilgrims were ‘at risk’, but this proportion varied from 
12.8% in 2013 to 27.8% in 2005. 
The uptake of combined influenza and pneumococcal 
vaccines ranged from 0.32% in 2007 to 24.4% in 2012, 
with the mean of 13.8% in the pooled sample with no 
significant trend of change (R2 = 0.5), but the rate of ARTI 
(i.e., combined cough and fever) ranged from 2.2% in 2014 
and 2.9% in 2015 to 46.3% in 2005 with the mean rate of 
5.3% in the pooled sample and showed an overall declining 
trend (R2 = 0.8) (Fig. 2). However, when the prevalence of 
ARTIs was computed against the uptake of vaccination, 
the RR showed a high variability from being ineffective in 
2011 (RR 1.9, 95% CI 1.1–3.17) and 2014 (HR 2.2, 95% 
CI 1.1–4.5) to being effective in 2009 (RR 0.2, 95% CI 
0.06–0.73), in the other years no significant effectiveness 
(or ineffectiveness) of vaccination was observed, and in the 
pooled sample vaccination was not effective (RR 1.1, 95% 
CI 0.8–1.4) (Table 1). 
DISCUSSION
The findings of this analysis highlight that the preva-
lence of ‘cough and fever’ among Hajj pilgrims is on decline 
but the uptake of combined influenza and pneumococcal 
vaccines remains unchanged over years (Fig. 2), and the 
decline can not be attributed to dual vaccination (RR = 1.1, 
95% CI 0.8–1.4). 
The decline in the prevalence of cough and fever symp-
toms could be purely because of influenza vaccination as 
was seen in previous analyses, including a meta-analysis 
of six studies (RR 0.56, 95% CI 0.41–0.75, p < 0.001) [13, 
14, 16], or because of overall improvement in infection con-
trol programmes [17], or because of change in Hajj seasons 
from colder months a decade ago to warmer months in re-
cent years, or it just could be an inexplicable chance finding.
Although no protective effect of dual influenza and pneu-
mococcal vaccination was observed in this analysis, benefit 
of dual vaccination was noted in a cohort study involving 
295 Iranian pilgrims during the Hajj 2005 when a significant 
reduction in the duration of cough, by almost 6 days, was 
noticed compared to no vaccination (p < 0.01) [18]. Beneficial 
effect was also noted in the French study included in this 
synthesis where fever was less frequently reported in pilgrims 
who were vaccinated against pneumococcal disease (plus in-
fluenza) (8.3% vs. 14.6%; RR = 0.22, 95% CI 0.06–0.73) [15].
Lack of apparent benefit of dual influenza and pneu-
mococcal vaccination against ARTI may have stemmed 
from several reasons: a) in our analysis ‘cough’ and ‘fever’ 
have been used a proxy for ARTIs but those two symptoms 
may represent an array of respiratory and non-respiratory 
conditions not just influenza and pneumonia; b) only a small 
proportion of pilgrims (13.8%) received both vaccines, this 
small vaccination rate may not have a discernible impact 
on two common respiratory symptoms; c) the pneumo-
coccal vaccine used here is a  23-valent polysaccharide 
vaccine which is primarily used to protect against invasive 
pneumococcal disease not necessarily pneumococcal 
pneumonia [19]. Systematic reviews of studies involving 
non-Hajj settings consistently showed that dual influenza 
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Figure 2. Line diagram showing the prevalence of cough and fever (proxy for acute respiratory tract infections [ARTIs]) against the 
uptake of combined influenza and pneumococcal vaccines among Hajj pilgrims (the vaccination rate did not increase significantly, 
however, the prevalence of cough and fever decreased)
and pneumococcal vaccination is associated with a  sig-
nificantly lower pneumonia rate and significantly lower 
pneumonia-associated mortality than influenza vaccination 
alone [20, 21]. No apparent effect of combined influenza 
and pneumonia vaccines among Hajj pilgrims observed in 
this analysis, compared to significant effect of influenza 
vaccine alone observed in other analyses, brings this syn-
thesis into question. Despite this non-conclusive finding 
vaccinations are highly desirable. Serious epidemics such as 
the outbreaks of meningococcal group A in 1987 and then 
group W in 2000–2001 have been brought under control 
by mandatory vaccinations [5, 22], actually the effect was 
so sustained that the mean annual meningococcal disease 
rates decreased from 0.20 cases/100,000 in pre-epidemic 
era to 0.06 cases/100,000 in post-epidemic period and 
mean numbers of Hajj-related cases from 13 to 2 cases/
year (p < 0.01) [8].
In this analysis the uptake of combined influenza and 
pneumococcal vaccines among Hajj pilgrims was poor. 
Recommendation of these vaccines for pilgrims also varies 
while the routine use of influenza vaccination is considered 
very important (even mandatory by some authorities) [11], 
pneumococcal vaccine is primarily considered for ‘at risk’ 
pilgrims [12, 23]. Hence individually, even though influenza 
vaccination rate has increased over the years in pilgrims 
from resource-rich countries [13, 24, 25], the uptake of 
pneumococcal vaccine remains suboptimal [26, 27]. Lack 
of awareness about the availability of the vaccines was the 
main reason for non-receipt of pneumococcal vaccine [28].
It is surprisingly disappointing to note that in 2 years 
(2011 and 2014), receipt of influenza and pneumococcal 
vaccines was associated with a  significant risk of ARTIs 
(Table 1). The reason for this paradoxical finding is unclear 
but the analysis has major limitations. First: smaller sample 
sizes in some years (e.g., in 2011 and 2005) are significant 
limitations. Data are unavailable for the years 2006, 2008, 
2009, 2010, 2016 and 2017, and the 2009 data have been 
obtained from a published study where the definition of ARTI 
has deviated slightly from the rest of the analysis [15]. The 
constructed trend line, therefore, would not represent the 
real effect of vaccinations on ARTI. Furthermore, some data 
generated from clinical trials that examined the effect of 
an intervention (e.g., facemask) [29, 30], so the observed 
effect (decline in ARTI prevalence) could also be attributed 
to the effect of those interventions.
Second: there are variations in the participants’ gender 
in the studied sample; it was skewed towards male gender in 
some years (2005, 2007, 2012, and 2013) and towards fe-
male in the other years. However, this variation was buffered in 
the pooled sample where female to male ratio was close to one.
Third: although pneumococcal vaccine is mostly recom-
mended for Hajj pilgrims aged ≥ 65 years and individuals 
with pre-existing medical conditions [12], this analysis en-
compassed individuals of all age groups and irrespective of 
risk conditions; therefore, does not indicate a true relation-
ship between pneumococcal vaccination and ARTI. 
Fourth: ARTI was defined by a presence of cough and 
subjective fever. These symptoms could be caused by 
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viruses and bacterial infections besides influenza and pneu-
mococci; sensitivity and specificity of this definition may 
not be optimum.
Fifth: vaccination data are subject to recall bias since the 
data were obtained by asking pilgrims about their vaccina-
tion history, not from their medical or vaccination records. 
This affects the validity of the data. 
Sixth: the original studies from where these data were 
obtained differed widely in their designs (i.e., surveillance 
data, questionnaire-based survey, pilot clinical trial, and ran-
domised controlled trial). This variation may have affected 
the quality of the aggregated data. 
Seventh: the last 2 years (2014, 2015) disproportion-
ately represented a large proportion (73.4%) of the pooled 
data skewing the results.
Finally, the studies were conducted in different seasons 
involving varying populations with varying health behaviours, 
nutritional status, immunity and background pre-existing 
illnesses compromising the homogeneity of the data and 
quality of the synthesis.  
Despite these limitations, there are a couple of unique 
strengths of this study. This is the first ever analysis of dual in-
fluenza and pneumococcal vaccination among Hajj pilgrims 
with a  relatively large sample of over 9000 pilgrims, and 
a large part of the data have been taken from meticulously 
conducted clinical trials (2013–2015, and 2011). 
The pneumococcal vaccine studied here is a 23-valent 
polysaccharide vaccine, currently conjugate pneumococcal 
vaccines of different valencies covering 7, 10 and 13 se-
rotypes are available [31]. The effectiveness of the newer 
conjugate vaccines against ARTI among Hajj pilgrims re-
mains unclear at this stage but the significant burden of 
pneumococcal disease at Hajj means that such vaccines 
will make a difference [32].
CONCLUSIONS
The risk of ARTI against the uptake of influenza and 
pneumococcal vaccines among Hajj pilgrims is still unclear. 
The coverage of these vaccines together is very low, but the 
prevalence of ‘cough and fever’ seems to have declined in 
the last several years. The data and their synthesis have 
limitations, so it is not known whether the decline in prev-
alence is due to slight (non-significant) increase in vaccine 
coverage or because of other factors. Further studies with 
more validated and homogenous data are needed to dispel 
the myth.
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